Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Infectious Diseases: Pathogenesis and Therapy
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1428569

Development and validation of a multivariable nomogram predictive of HBeAg seroconversion after pregnancy in HBV-infected mothers

Provisionally accepted
Wenting Zhong Wenting Zhong Jie Zheng Jie Zheng Che Wang Che Wang Lei Shi Lei Shi Yingli He Yingli He Yingren Zhao Yingren Zhao Tianyan Chen Tianyan Chen *
  • Department of Infectious Disease, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

The final, formatted version of the article will be published soon.

    Background and Aims:Current guidelines are controversial regarding the continuation of nucleos(t)ide analogues(NAs) therapy after delivery in Hepatitis B virus(HBV)-infected pregnant women.The postpartum period may be an opportune moment for achieving hepatitis B e antigen(HBeAg) seroconversion earlier with constant NAs therapy due to the restoration of immune function after delivery.We investigated prenatal and pregnant factors associated with HBeAg seroconversion after pregnancy and developed a nomogram to predict HBeAg seroconversion rates,aiding decision-making for optimal management in women.: We retrospectively included 489 HBeAg-positive mothers as the training cohort from January 2014 to December 2018 and prospectively enrolled 94 patients as the external validation cohort from January 2019 to December 2021 at the First Affiliated Hospital of Xi'an Jiaotong University.In the training cohort, independent predictors were identified using the least absolute shrinkage and selection operator(LASSO) regression algorithm. Subsequently, multivariate logistic regression was employed to establish the nomogram.Model performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis (DCA).Both discrimination and calibration were evaluated through bootstrapping with 1000 resamples.The external validation cohort was subsequently used to validate the nomogram. Results:Factors such as pregnancy hepatitis flare(OR:5.122,95%CI:2.725-9.928,P<0.001),NAs therapy after delivery(OR:15.051,95%CI:6.954-37.895,P:<0.001),hepatitis B surface antigen(HBsAg)(OR:0.549,95%CI:0.366-0.812,P:0.003) and HBV DNA level at delivery(OR:0.785,95%CI:0.619-0.986,P:0.041) were included in the final risk model.The AUC in the training set was 0.873(95%CI:0.839-0.904).The calibration curve of the nomogram closely resembled the ideal diagonal line.DCA showed a significantly better net benefit in the model.External validation also confirmed the reliability of the prediction nomogram.The AUC in the external validation set was 0.889 (95% CI: 0.801-0.953).The calibration curve for the external validation set was in close proximity to the ideal diagonal line.DCA also demonstrated a significant net benefit associated with the predictive model,consistent with the findings in the training set.Finally,the nomogram has been translated into an online risk calculator that is freely available to the public (https://wendyzhong.shinyapps.io/DynNomapp/).HBeAg seroconversion after delivery in women.This tool provides clinicians with a precise and effective way to identify individuals likely to undergo HBeAg seroconversion postpartum,aiding in decision-making for optimal management.

    Keywords: HBV, HBeAg seroconversion, postpartum therapy, nomogram, HBV-infected mother, MTCT, pregnancy hepatitis flare, Prediction model

    Received: 04 Jun 2024; Accepted: 07 Oct 2024.

    Copyright: © 2024 Zhong, Zheng, Wang, Shi, He, Zhao and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Tianyan Chen, Department of Infectious Disease, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.